Lifeward (Nasdaq:LFWD) received CE mark approval for its ReWalk 7 personal exoskeleton.
ReWalk 7, the seventh generation of the company’s personal exoskeleton, includes a number of new features, enhancements and upgrades to provide a more functional and personalized walking experience for individuals with spinal cord injury (SCI). Those include cloud connectivity and customizable walking speeds for users. The system also enables push-button control and seamless activation of stairs and curbs.
Related: ClearPoint Neuro wins expanded clearance for Prism Neuro Laser Therapy System
Lifeward says the new system allows users to walk longer and more often with an improved battery and seamless activation of stairs and curbs. Additionally, the all-new therapist handheld device and click-to-stop control enables safer, more effective progression to optimal gait patterns.
Marlborough, Massachusetts-based Lifeward (formerly ReWalk Robotics) said Europe currently represents 40% of its exoskeleton sales.
The initial CE mark for ReWalk exoskeletons came in 2010, with the company rolling out the previous generations over the past several years. ReWalk 7 also holds FDA clearance, receiving the nod in March. Lifeward then launched the next-generation system in the U.S. the following month.
“The ReWalk 7 represents a major advancement in personal exoskeleton technology, designed to deliver superior control, engagement, and real-world mobility for individuals with spinal cord injury (SCI),” said Mark Grant, CEO of Lifeward. “Achieving CE mark approval is a pivotal regulatory milestone for Lifeward. With reimbursement already broadly established in Germany, this foundation positions us to drive meaningful near-term commercial adoption and revenue growth in Europe, while also providing a proven model we are beginning to replicate in other strategic markets, including the United States.”
